Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,647 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).
Nokihara H, Lu S, Mok TSK, Nakagawa K, Yamamoto N, Shi YK, Zhang L, Soo RA, Yang JC, Sugawara S, Nishio M, Takahashi T, Goto K, Chang J, Maemondo M, Ichinose Y, Cheng Y, Lim WT, Morita S, Tamura T. Nokihara H, et al. Among authors: goto k. Ann Oncol. 2017 Nov 1;28(11):2698-2706. doi: 10.1093/annonc/mdx419. Ann Oncol. 2017. PMID: 29045553 Free PMC article. Clinical Trial.
A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients.
Ohe Y, Niho S, Kakinuma R, Kubota K, Ohmatsu H, Goto K, Nokihara H, Kunitoh H, Saijo N, Aono H, Watanabe K, Tango M, Yokoyama A, Nishiwaki Y. Ohe Y, et al. Among authors: goto k. Ann Oncol. 2004 Jan;15(1):45-50. doi: 10.1093/annonc/mdh015. Ann Oncol. 2004. PMID: 14679118 Free article. Clinical Trial.
Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.
Kanda S, Goto K, Shiraishi H, Kubo E, Tanaka A, Utsumi H, Sunami K, Kitazono S, Mizugaki H, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Hozumi H, Tamura T. Kanda S, et al. Among authors: goto k. Ann Oncol. 2016 Dec;27(12):2242-2250. doi: 10.1093/annonc/mdw416. Epub 2016 Oct 20. Ann Oncol. 2016. PMID: 27765756 Free PMC article. Clinical Trial.
Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study.
Yamamoto N, Seto T, Nishio M, Goto K, Yamamoto N, Okamoto I, Yamanaka T, Tanaka M, Takahashi K, Fukuoka M. Yamamoto N, et al. Among authors: goto k. Lung Cancer. 2021 Jan;151:20-24. doi: 10.1016/j.lungcan.2020.11.020. Epub 2020 Nov 20. Lung Cancer. 2021. PMID: 33279874 Free article. Clinical Trial.
Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer.
Goto K, Sekine I, Nishiwaki Y, Kakinuma R, Kubota K, Matsumoto T, Ohmatsu H, Niho S, Kodama T, Shinkai T, Tamura T, Ohe Y, Kunitoh H, Yamamoto N, Nokihara H, Yoshida K, Sugiura T, Matsui K, Saijo N. Goto K, et al. Br J Cancer. 2004 Aug 16;91(4):659-65. doi: 10.1038/sj.bjc.6602056. Br J Cancer. 2004. PMID: 15280919 Free PMC article. Clinical Trial.
Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study.
Suzuki K, Yamanaka T, Hashimoto H, Shimada Y, Arata K, Matsui R, Goto K, Takiguchi T, Ohyanagi F, Kogure Y, Nogami N, Nakao M, Takeda K, Azuma K, Nagase S, Hayashi T, Fujiwara K, Shimada T, Seki N, Yamamoto N. Suzuki K, et al. Among authors: goto k. Ann Oncol. 2016 Aug;27(8):1601-6. doi: 10.1093/annonc/mdw220. Epub 2016 Jun 29. Ann Oncol. 2016. PMID: 27358385 Free article. Clinical Trial.
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
Oxnard GR, Yang JC, Yu H, Kim SW, Saka H, Horn L, Goto K, Ohe Y, Mann H, Thress KS, Frigault MM, Vishwanathan K, Ghiorghiu D, Ramalingam SS, Ahn MJ. Oxnard GR, et al. Among authors: goto k. Ann Oncol. 2020 Apr;31(4):507-516. doi: 10.1016/j.annonc.2020.01.013. Epub 2020 Jan 24. Ann Oncol. 2020. PMID: 32139298 Free article. Clinical Trial.
Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer.
Hotta K, Hida T, Nokihara H, Morise M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Kumagai T, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Yoshimoto T, Takata S, Tamura T. Hotta K, et al. Among authors: goto k. ESMO Open. 2022 Aug;7(4):100527. doi: 10.1016/j.esmoop.2022.100527. Epub 2022 Jul 14. ESMO Open. 2022. PMID: 35843080 Free PMC article. Clinical Trial.
3,647 results